These GLP-1 agonists can be a two-in-one solution for diabetes and weight loss, Robert Fontana, MD, a Michigan Medicine hepatologist said in an online interview, maybe a three-in-one solution if they prove to be safe and effective for metabolic associated steatohepatitis as well. When asked about the benefits observed in patients using GLP-1RA medications for conditions other than diabetes, the top five areas of improvement that physicians reported included weight loss (92 percent), positive effects on lipid profiles (57 percent), reduced cravings or dependency behaviors (56 percent), reduced blood pressure (48 percent), and reduced inflammation (46 percent)
According to the Mass Eye and Ear study: 8.9% of diabetic patients taking semaglutide received a NAION diagnosis
(2022) [59] comparing GLP-1RA plus SGLT2i combination therapy to GLP-1RA and SGLT2i monotherapies among 1,895 patients with T2DM enrolled in 8 RCTs, the addition of a GLP-1RA to SGLT2i treatment showed that drug discontinuation, diarrhea, injection-site-related events, nausea, vomiting and genital infections were more likely to occur in combination therapy
The thought process behind this notion is clever, but does it actually have any real-world basis
Transdifferentiation of bone-marrow derived stem cells is infrequent in organs and absent in tumor metastases
-agonists-market-key-insight.png)
